Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
GLP-1 obesity pills face off in head-to-head trial
12:39pm, Friday, 12'th Sep 2025
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
12:13pm, Friday, 12'th Sep 2025
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 12'th Sep 2025
LOS ANGELES , Sept. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
06:45pm, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit – NVO
04:24pm, Thursday, 11'th Sep 2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
03:43pm, Thursday, 11'th Sep 2025
It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard H
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on b
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Novo Nordisk tells staff to return to office full-time amid CEO's revival effort
09:41am, Thursday, 11'th Sep 2025
Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid in
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
08:45am, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
The complaint alleges Novo overstated GLP-1 growth prospects; stock dropped 21.83% after lowered sales outlook citing compounded GLP-1 use and competition.
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
04:59am, Thursday, 11'th Sep 2025
Finding undervalued stocks isn't easy these days. The average stock price for companies in the benchmark S&P 500 index has soared to 24.8 times trailing 12-month earnings.
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
03:51pm, Wednesday, 10'th Sep 2025
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroa
